Back To Search Results

Primary Amenorrhea

Editor: Anis Rehman Updated: 3/30/2023 1:01:08 PM

Amenorrhea is defined as the absence of menarche in females of reproductive age. Primary amenorrhea is defined as the failure to reach menarche. Evaluation should be undertaken if there are no secondary sex characteristics by 13 years of age, if menarche has not occurred five years after initial breast development, or if the patient is 15 years or older. In contrast, secondary amenorrhea is defined as the cessation of previous menses for more than 6 months.[1]


Earn CME credit as you help guide your clinical decisions.
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed.


$59 per month


$599 per year

The majority of cases of primary amenorrhea are caused by anatomical defects, elevated follicle-stimulating hormone (FSH) levels, hyperprolactinemia, hypothalamic amenorrhea, or polycystic ovary syndrome (PCOS).[2]

Gonadal dysgenesis includes most commonly Turner syndrome, which makes up to 43% of primary amenorrhea cases. 

Anatomical Defects 

When the uterus and vagina are partially or completely absent in the presence of otherwise normal female sexual characteristics, the diagnosis is typically Mullerian agenesis, which accounts for approximately 10% of primary amenorrhea cases. Other anatomical defects include imperforate hymen or transverse vaginal septum, both of which create a partial or complete vaginal blockage, and isolated absence of the vagina or cervix.[3]

Elevated FSH Levels

Elevated follicle-stimulating hormone levels can indicate gonadal dysfunction. In individuals with XX chromosomes, gonadal failure refers to ovarian failure.[3]  


Prolactin is a pituitary hormone that is involved in many reproductive functions. The secretion of prolactin causes an inhibition of the secretion of gonadotropin-releasing hormone, which negatively modulates the secretion of pituitary hormones responsible for the gonadal function.[4]  

Hypothalamic Amenorrhea 

This condition causes cessation or absence of menses due to a functional disorder of the hypothalamus. 

Polycystic Ovary Syndrome

PCOS is the most common cause of amenorrhea in females with evidence of androgen excess. It is a common reproductive and endocrinologic disorder. The three main characteristics of this syndrome are hyperandrogenism, polycystic ovaries, and ovulatory dysfunction.[5]

Hypopituitarism, weight loss, anorexia nervosa, and isolated gonadotropin-releasing hormone (GnRH) deficiency can also cause amenorrhea.

Constitutional delay of puberty and chronic systemic disease or acute illness can also lead to amenorrhea. 

The World Health Organization (WHO) categorized amenorrhea into three groups. WHO group I includes females with no evidence of endogenous estrogen production, normal or low follicle-stimulating hormone (FSH) levels, normal prolactin levels, and no evidence of lesions in the hypothalamic-pituitary region. WHO group II includes females who can produce estrogen and have normal levels of prolactin and FSH. WHO group III includes females with increased serum FSH, which indicates gonadal insufficiency or failure.[6][7]

The incidence of primary amenorrhea is less than 1% in the United States. No variation is seen in the overall prevalence of primary amenorrhea according to the ethnic group or national origin.

The menstrual cycle is a series of coordinated hormonal changes controlling the ovaries and endometrium that stimulate the growth of a follicle to release an egg and prepare the endometrium for implantation if fertilization should occur. Conversely, if the egg released is not fertilized, menstruation occurs due to the shedding of the functional layer of the endometrium. The basic requirements for normal menstrual function include four anatomically and functionally distinct structural components: the genital outflow tract, including the uterus, the ovaries, the pituitary gland, and the hypothalamus. If any of the components are non-functional, bleeding cannot occur.[8][9]

History and Physical

The evaluation of amenorrhea begins with a thorough medical history and physical examination. It is important first to rule out pregnancy as a patient ovulates before their first period. Inquire about pubertal development or cyclic abdominal pain, which may be caused by an imperforate hymen, transverse vaginal septum, or cervical atresia. Any history of anosmia, galactorrhoea, headaches, or visual changes may indicate a central nervous system or pituitary disorder. Inquire about medical history, general health, and lifestyle, particularly to identify chronic illness or exposure to radiation. Current medications should be reviewed. A history of extreme weight loss should be noted. Delayed menarche or androgen insensitivity syndrome can often be hereditary.[10][11]

Physical examination includes measurement of height, weight, and BMI. Short stature and sexual infantilism are hallmarks of gonadal dysgenesis. Low body weight is associated with hypothalamic amenorrhea resulting from severe malnutrition or physical, psychological, or emotional stress. Breast tanner staging is a reliable indicator of estrogen production or exposure to exogenous estrogen. A goiter or thyroid nodule suggests thyroid disorder; both hypothyroidism and hyperthyroidism can be associated with amenorrhea. Stigmata of Turner's syndrome should be explored, including a webbed neck, widely spaced nipples, cubitus valgus, low hairline, high arched palate, multiple pigmented naevi, and short fourth metacarpals. Abdominal examination may reveal a mass that may result from hematometra or an ovarian neoplasm, but this is rare. A thorough examination of the external genitalia should be conducted. An imperforate hymen is diagnosed by the presence of a bulging membrane that distends during the Valsalva maneuver. A patent vagina and normal cervix exclude Mullerian vaginal agenesis, androgen insensitivity syndrome, and obstructive causes of amenorrhea such as an imperforate hymen or transverse vaginal septum. Rectal examination can detect any distended haematocolpos that may form above the obstruction when the uterus is present and functional.[10][12]


In assessing the reason for amenorrhea, a pregnancy test should first be conducted. The Tanner scale should be used to stage pubertal development to determine whether secondary sexual characteristics are present. The absence of secondary sexual characteristics indicates that a woman has never been exposed to estrogen. Pelvic ultrasound should be conducted to confirm the presence or absence of a uterus. Initial laboratory tests can determine the serum levels of serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels unless the history and physical examination indicate otherwise - this can help to discern hypergonadotropic and hypogonadotropic forms of hypogonadism. If the screening FSH level is low, the diagnosis of hypogonadotropic hypogonadism can be confirmed. Other important blood investigations include measurement of serum thyroid-stimulating hormone level and serum prolactin level. Elevated serum FSH level indicates premature ovarian insufficiency or failure. A karyotype should be conducted in patients under 30-years-old.

A karyotype is also useful in diagnosing androgen insensitivity syndrome, Turner syndrome, Mullerian anomalies, and gonadal dysgenesis. Due to the association between Turner Syndrome and coarctation of the aorta, patients should have an echocardiograph conducted every 3 to 5 years. The presence of the Y chromosome, along with raised serum testosterone levels, point towards the diagnosis of androgen insensitivity. If the karyotype is normal with an elevated FSH level, 17-hydroxylase deficiency should be considered, as it can be life-threatening if left untreated. Testing can be done with serum measurement of 17 alpha-hydroxyprogesterone and deoxycorticosterone levels. The diagnosis is established with an adrenocorticotropic hormone (ACTH) stimulation test. Ultrasonography or MRI is useful to identify the Mullerian anomaly when the abnormality cannot be found by physical examination. Lesions of the central nervous system should be excluded through the use of imaging using CT or MRI, particularly if headaches, visual impairments, or galactorrhea are present.[13][14]

Treatment / Management

For the treatment of congenital anomalies:[15][14]

  1. Treatment of imperforate hymen involves making a cruciate incision to open the vaginal orifice.
  2. If a transverse septum is present, surgical removal is required.
  3. Hypoplasia or absence of the cervix in the presence of a functioning uterus is more difficult to treat than other outflow obstructions. Surgery to repair the cervix is rarely successful, and hysterectomy is typically required. The ovaries should be retained to provide the benefits of estrogen and to allow for the possibility of future childbearing by removing mature oocytes for in vitro fertilization and transfer of embryos to a gestational carrier.
  4. If the vagina is absent or short, progressive dilation is usually successful.

Females diagnosed with primary amenorrhea associated with all forms of gonadal failure and hypergonadotropic hypogonadism require cyclic estrogen and progestogen therapy for the initiation, maturation, and maintenance of secondary sexual characteristics.

  1. Therapy can be initiated with conjugated estrogens per day or estradiol per day.
  2. Females with short stature should not receive high doses of estrogen as this can cause the epiphyses to close prematurely.
  3. Hyperplasia can occur due to unopposed estrogen stimulation of the endometrium. To prevent hyperplasia, estrogen can be provided daily in combination with progestogen.
  4. Patients with gonadal streaks and mosaicism may be able to ovulate and conceive either following the initiation of estrogen therapy or spontaneously.
  5. If the diagnosis of 17 alpha-hydroxylase deficiency is established, treatment can be initiated with exogenous corticosteroid replacement therapy with either hydrocortisone or dexamethasone.

Therapeutic measures should aim to target the underlying cause or primary amenorrhea.

  1. Craniopharyngiomas may be resected either during craniotomy or with a transsphenoidal approach.
  2. Germinomas are very radiosensitive; thus, surgery is seldom indicated.
  3. Hyperprolactinemia and prolactinomas may respond to dopamine agonists.
  4. Specific therapies can target underlying causes such as anorexia nervosa or malnutrition.
  5. Individuals diagnosed with Kallman syndrome or other etiologies for hypothalamic amenorrhea may be treated with hormone replacement therapy. 

If a female's karyotype contains the Y chromosome, such as gonadal dysgenesis, gonad removal should be performed to prevent tumors.

Differential Diagnosis

The differential diagnoses are as follows: 

  • Primary hypothalamic amenorrhea 
  • Emotional/physical stress 
  • Female athlete triad 
  • Hypogonadotropic hypogonadism (Kallman syndrome)
  • Malnutrition 
  • Chronic disease state
  • Constitutional delay
  • PCOS
  • Outflow tract obstruction 


Primary amenorrhea is not a life-threatening disease but can result in significant complications.


If primary amenorrhea is associated with decreased estrogen levels, it can cause an increased risk of bone fractures due to reduced bone density from osteoporosis.[16]

Deterrence and Patient Education

Due to the diversity of etiologies that can lead to primary amenorrhea, patient education should be individualized to the underlying cause. Females nearing the age of puberty should be educated on normal menstrual periods and when to schedule a follow-up with a physician. Patients being treated for primary amenorrhea should regularly follow up with their physician.

Enhancing Healthcare Team Outcomes

Primary amenorrhea poses a diagnostic dilemma. These patients present with specific signs and symptoms which point toward the underlying etiology. A detailed history and thorough physical examination help in reaching the diagnosis in most cases. However, diagnosis is further supported in some patients by an array of laboratory investigations, including serum measurement of thyroid function tests, FSH, LH, and prolactin, using radiological imaging, and obtaining the karyotype. Treatment is aimed at correcting the primary cause of amenorrhea. Treatment is primarily surgical in which congenital anomalies are found to be the cause of primary amenorrhea. Cyclic hormonal therapy is instituted in all cases of premature ovarian failure and gonadal dysgenesis. An interprofessional team that includes clinicians (MDs, DOs, NPs, PAs), specialists (particularly endocrinologists and gynecologists), nurses, and pharmacists must work collaboratively, openly share information, and coordinate in educating the patient and monitoring treatment, leading to optimal patient outcomes with the fewest adverse events.[11] [Level 5]



Lord M,Sahni M, Amenorrhea, Secondary 2019 Jan;     [PubMed PMID: 28613709]


Practice Committee of American Society for Reproductive Medicine. Current evaluation of amenorrhea. Fertility and sterility. 2008 Nov:90(5 Suppl):S219-25. doi: 10.1016/j.fertnstert.2008.08.038. Epub     [PubMed PMID: 19007635]


Majumdar A, Mangal NS. Hyperprolactinemia. Journal of human reproductive sciences. 2013 Jul:6(3):168-75. doi: 10.4103/0974-1208.121400. Epub     [PubMed PMID: 24347930]


Barthelmess EK, Naz RK. Polycystic ovary syndrome: current status and future perspective. Frontiers in bioscience (Elite edition). 2014 Jan 1:6(1):104-19     [PubMed PMID: 24389146]

Level 3 (low-level) evidence


Yang P, Liu X, Gao J, Qu S, Zhang M. Complete androgen insensitivity syndrome in a young woman with metabolic disorder and diabetes: A case report. Medicine. 2018 Aug:97(33):e11353. doi: 10.1097/MD.0000000000011353. Epub     [PubMed PMID: 30113450]

Level 3 (low-level) evidence


Wei HL, Lu S, Wang XL, Li JW, Cui YP, Yao YS. [17α-Hydroxylase deficiency with severe hypertension as the initial symptom in a child]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics. 2018 Aug:20(8):675-679     [PubMed PMID: 30111479]


Sarathi V, Reddy R, Atluri S, Shivaprasad C. A challenging case of primary amenorrhoea. BMJ case reports. 2018 Jul 11:2018():. pii: bcr-2018-225447. doi: 10.1136/bcr-2018-225447. Epub 2018 Jul 11     [PubMed PMID: 30002216]

Level 3 (low-level) evidence


Klein DA, Paradise SL, Reeder RM. Amenorrhea: A Systematic Approach to Diagnosis and Management. American family physician. 2019 Jul 1:100(1):39-48     [PubMed PMID: 31259490]

Level 1 (high-level) evidence


Jacobson MH, Howards PP, Darrow LA, Meadows JW, Kesner JS, Spencer JB, Terrell ML, Marcus M. Thyroid hormones and menstrual cycle function in a longitudinal cohort of premenopausal women. Paediatric and perinatal epidemiology. 2018 May:32(3):225-234. doi: 10.1111/ppe.12462. Epub 2018 Mar 8     [PubMed PMID: 29517803]


Lang-Muritano M, Sproll P, Wyss S, Kolly A, Hürlimann R, Konrad D, Biason-Lauber A. Early-Onset Complete Ovarian Failure and Lack of Puberty in a Woman With Mutated Estrogen Receptor β (ESR2). The Journal of clinical endocrinology and metabolism. 2018 Oct 1:103(10):3748-3756. doi: 10.1210/jc.2018-00769. Epub     [PubMed PMID: 30113650]


Master-Hunter T, Heiman DL. Amenorrhea: evaluation and treatment. American family physician. 2006 Apr 15:73(8):1374-82     [PubMed PMID: 16669559]


Bettencourt-Silva R, Pereira J, Belo S, Magalhães D, Queirós J, Carvalho D. Prolactin-Producing Pituitary Carcinoma, Hypopituitarism, and Graves' Disease-Report of a Challenging Case and Literature Review. Frontiers in endocrinology. 2018:9():312. doi: 10.3389/fendo.2018.00312. Epub 2018 Jun 6     [PubMed PMID: 29928263]

Level 3 (low-level) evidence


Eggermann T, Ledig S, Begemann M, Elbracht M, Kurth I, Wieacker P. Search for altered imprinting marks in Mayer-Rokitansky-Küster-Hauser patients. Molecular genetics & genomic medicine. 2018 Nov:6(6):1225-1228. doi: 10.1002/mgg3.426. Epub 2018 Aug 11     [PubMed PMID: 30099855]


Deligeoroglou E, Athanasopoulos N, Tsimaris P, Dimopoulos KD, Vrachnis N, Creatsas G. Evaluation and management of adolescent amenorrhea. Annals of the New York Academy of Sciences. 2010 Sep:1205():23-32. doi: 10.1111/j.1749-6632.2010.05669.x. Epub     [PubMed PMID: 20840249]


Tavera G, Lazebnik R. Müllerian Agenesis Masquerading as Secondary Amenorrhea. Case reports in pediatrics. 2018:2018():6912351. doi: 10.1155/2018/6912351. Epub 2018 Jul 19     [PubMed PMID: 30123604]

Level 3 (low-level) evidence


Gordon CM, Nelson LM. Amenorrhea and bone health in adolescents and young women. Current opinion in obstetrics & gynecology. 2003 Oct:15(5):377-84     [PubMed PMID: 14501240]

Level 3 (low-level) evidence


Sharp HT, Johnson JV, Lemieux LA, Currigan SM. Executive Summary of the reVITALize Initiative: Standardizing Gynecologic Data Definitions. Obstetrics and gynecology. 2017 Apr:129(4):603-607. doi: 10.1097/AOG.0000000000001939. Epub     [PubMed PMID: 28277367]


. ACOG Committee Opinion No. 651: Menstruation in Girls and Adolescents: Using the Menstrual Cycle as a Vital Sign. Obstetrics and gynecology. 2015 Dec:126(6):e143-e146. doi: 10.1097/AOG.0000000000001215. Epub     [PubMed PMID: 26595586]

Level 3 (low-level) evidence


He Q, Karlberg J. Bmi in childhood and its association with height gain, timing of puberty, and final height. Pediatric research. 2001 Feb:49(2):244-51     [PubMed PMID: 11158521]